ClinicalTrials.gg
Not yet recruitingNCT07858435IO-CAPAUpdated Oct 5, 2026

Intra-ovarian CAPA-IVM vs Standard IVM

An interventional study of CAPA-IVM and In-House CAPA-IVM Pre-Maturation Medium in Infertility (IVF Patients), Infertility and Infertility Female, sponsored by New Hope Fertility Center. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 38 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionInfertility, FemaleRegistry: InfertilityReclassifiedWhy we changed it
Registry
Infertility — the first condition term the registry derived for this study.
ClinicalTrials.gg
Infertility, Female
Why
  1. The study's listed conditions name Infertility, Female, a narrower term within Infertility.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by New Hope Fertility Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 38 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 24 under way, none of them phase 3. Infertility, Female · United States.

Planned enrollment
33rd of 47
20 · median 50
Started
2026
with 3 others
No phase
30 of 65
11 open now
Primary completion
2027-03
later than 12 of 23 live
Registered
65th of 65
by date

Among the 65 studies in Infertility, Female with a site in United States, this one is the 33rd largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2026, is one of 30 with no phase, reaches primary completion later than 12 of the 23 other live ones, and was the 65th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 38 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Infertility, Female with a site in United States, or all of them as a file.
02

Study summary

This prospective study compares two approaches to obtaining mature oocytes for fertility treatment within the same participant. Immature oocytes are first retrieved from the right ovary and matured in the laboratory using a two-step biphasic capacitation in vitro maturation method (CAPA-IVM). Beginning on Day 5 of the same menstrual cycle, the left ovary undergoes minimal controlled ovarian stimulation followed by routine oocyte retrieval and IVF/ICSI.

The primary objective is to evaluate the maturation of CAPA-IVM oocytes to the metaphase II (MII) stage and compare reproductive laboratory outcomes between the CAPA-IVM and minimal-stimulation OS-IVF approaches. Secondary outcomes include fertilization, embryo development, blastocyst formation, embryo quality, pregnancy and live birth outcomes, and safety.

Read the detailed description

This is a prospective, within-patient comparative study in women undergoing fertility treatment. Each participant serves as her own internal control. At the Day 3 baseline visit, the right ovary is assigned to the CAPA-IVM approach and the left ovary is assigned to minimal controlled ovarian stimulation followed by IVF/ICSI. Both approaches are performed within the same menstrual cycle.

For the CAPA-IVM arm, immature oocytes are retrieved from the right ovary beginning on or after menstrual cycle Day 3, before ovarian stimulation is initiated. The right ovary is not stimulated and does not receive an ovulation trigger before oocyte collection. Retrieved cumulus-oocyte complexes are handled separately, and immature oocytes at the germinal vesicle (GV) or metaphase I (MI) stage undergo a biphasic CAPA-IVM process consisting of an initial pre-maturation/capacitation phase followed by transfer to maturation conditions and assessment for development to the metaphase II (MII) stage.

After completion of right-ovary aspiration, minimal controlled ovarian stimulation of the left ovary begins on Day 5. The protocol uses clomiphene citrate for approximately 9 days and follitropin beta for approximately 3 days, with ultrasound and/or hormonal monitoring. Final oocyte maturation is initiated with leuprolide acetate as a GnRH-agonist trigger, followed by routine oocyte retrieval from the left ovary.

Mature oocytes obtained from both approaches may undergo ICSI according to New Hope Fertility Center clinical practice. Oocyte assessment and selection for ICSI, ICSI itself, and standard embryo culture are considered clinical procedures; the research-specific component is the CAPA-IVM maturation approach and the within-patient comparison of outcomes according to ovary of origin. Oocytes and embryos are tracked separately to maintain traceability throughout fertilization, embryo culture, and subsequent clinical outcomes.

The primary endpoint is the proportion of immature CAPA-IVM oocytes that mature to the MII stage. Secondary endpoints include fertilization rate, cleavage, blastocyst formation, high-quality blastocyst formation, implantation, clinical pregnancy, ongoing pregnancy, live birth, neonatal outcomes, and safety outcomes including procedure-related complications and ovarian reserve measures.

03

Conditions studied

  • Infertility (IVF Patients)
  • Infertility
  • Infertility Female

Browse trials for

Keywords

  • In Vitro Maturation
  • IVM
  • CAPA-IVM
  • Biphasic In Vitro Maturation
  • Oocyte Maturation
  • Oocyte
  • Assisted Reproductive Technology
  • IVF
  • ICSI
  • Minimal Ovarian Stimulation
  • Controlled Ovarian Stimulation
  • Embryo Development
  • Blastocyst Formation
  • Female Infertility
  • Within-Patient Comparison
04

In context

Infertility, Female Reclassified

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's planned enrollment of 20 is below the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

New Hope Fertility Center is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Infertility, Female, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, age 18 to 38 years.
  • Undergoing assisted reproductive treatment for infertility.
  • Both ovaries present and anatomically suitable for oocyte retrieval, with no prior oophorectomy.
  • Adequate ovarian reserve for study participation, including AMH greater than 0.5 ng/mL and antral follicle count greater than 6 per ovary.
  • Both ovaries considered suitable for their assigned study procedures: right ovary for CAPA-IVM and left ovary for minimal-stimulation OS-IVF.
  • Access to partner or donor sperm for fertilization/ICSI according to clinic protocol.
  • Willing and able to provide written and comply with study procedures and follow-up.

Exclusion criteria

Exclusion Criteria:

  • Severe endometriosis, Stage III or IV.
  • Known diminished ovarian reserve with AMH less than 0.2 ng/mL, unless specifically permitted under an approved study amendment.
  • Active pelvic infection.
  • Untreated hydrosalpinx.
  • Known chromosomal abnormality in either reproductive partner, unless appropriate genetic testing is planned.
  • to oocyte retrieval or sedation/anesthesia.
  • Any medical or gynecologic condition that, in the investigator's judgment, would interfere with study participation, oocyte retrieval, study procedures, or participant safety.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Within-Patient CAPA-IVM and Minimal-Stimulation OS-IVF

    All participants undergo a within-patient comparison in the same menstrual cycle. The right ovary undergoes retrieval of immature oocytes for CAPA-IVM beginning on or after menstrual cycle Day 3, before ovarian stimulation. The left ovary subsequently undergoes minimal controlled ovarian stimulation beginning on Day 5, followed by oocyte retrieval and standard IVF/ICSI. Outcomes are compared according to ovary and oocyte origin, with each participant serving as her own internal control.

    Procedure: CAPA-IVM · Device: In-House CAPA-IVM Pre-Maturation Medium · Procedure: Minimal-Stimulation OS-IVF

Interventions

  • ProcedureCAPA-IVM

    Immature cumulus-oocyte complexes are retrieved from the right ovary before ovarian stimulation and undergo a biphasic CAPA-IVM process. The first phase is a pre-maturation/capacitation culture intended to maintain meiotic arrest while supporting developmental competence. Oocytes are then transferred to maturation conditions and assessed for maturation to metaphase II (MII). Mature oocytes may subsequently undergo ICSI and standard embryo culture according to clinical practice.

  • DeviceIn-House CAPA-IVM Pre-Maturation Medium

    An investigational in-house reproductive culture medium is used during the pre-maturation/capacitation phase of CAPA-IVM for immature cumulus-oocyte complexes. The proprietary formulation is prepared for use in the CAPA-IVM laboratory procedure. Following the pre-maturation phase, oocytes are transferred to maturation conditions and assessed for MII maturation.

  • ProcedureMinimal-Stimulation OS-IVF

    After completion of right-ovary CAPA-IVM aspiration, minimal controlled ovarian stimulation of the left ovary begins on menstrual cycle Day 5. The regimen includes clomiphene citrate for approximately 9 days and follitropin beta for approximately 3 days with ultrasound and/or hormonal monitoring. Final oocyte maturation is initiated using leuprolide acetate as a GnRH-agonist trigger. Oocytes are subsequently retrieved from the left ovary and undergo standard IVF/ICSI and embryo culture according to clinical practice.

07

What researchers measure

Primary outcomes

  1. Maturation Rate to Metaphase II (MII) Following CAPA-IVM

    Proportion of immature oocytes retrieved from the CAPA-IVM ovary that reach the metaphase II (MII) stage after completion of the biphasic CAPA-IVM culture process. Maturation rate will be calculated as the number of oocytes reaching MII divided by the number of immature oocytes undergoing CAPA-IVM.

    Time frame: Up to approximately 54 hours after initiation of CAPA-IVM culture

Secondary outcomes

  1. Fertilization Rate

    Proportion of injected MII oocytes showing normal two-pronuclear (2PN) fertilization after ICSI, analyzed by ovary/treatment origin.

    Time frame: At fertilization assessment following ICSI

  2. Cleavage Rate

    Proportion of normally fertilized embryos that undergo cleavage by embryo culture Day 2-3.

    Time frame: Day 2-3 after fertilization

  3. Blastocyst Formation Rate

    Proportion of embryos developing to the blastocyst stage, analyzed according to CAPA-IVM or minimal-stimulation OS-IVF origin.

    Time frame: Day 5-6 after fertilization

  4. High-Quality Blastocyst Rate

    Proportion of embryos meeting the center's predefined criteria for high-quality blastocyst morphology.

    Time frame: Day 5-6 after fertilization

  5. Clinical Pregnancy Rate

    Proportion of embryo transfers resulting in a clinical pregnancy confirmed by ultrasound evidence of fetal cardiac activity.

    Time frame: Approximately 7-8 weeks gestation

  6. Ongoing Pregnancy Rate

    Proportion of embryo transfers resulting in an ongoing pregnancy beyond 12 weeks gestation.

    Time frame: Greater than 12 weeks gestation

  7. Live Birth Rate

    Proportion of embryo transfers resulting in a live birth. Outcomes will be analyzed according to embryo origin when traceable.

    Time frame: At delivery, up to approximately 10 months after embryo transfer

  8. Procedure-Related and Treatment-Related Adverse Events

    Incidence of adverse events including ovarian hyperstimulation syndrome, egg-retrieval complications, sedation/anesthesia complications, and other study-related adverse events.

    Time frame: From initiation of study treatment through 6 months after treatment

  9. Change in Serum Anti-Müllerian Hormone (AMH)

    Change in serum AMH concentration from baseline to the follow-up ovarian-reserve assessment.

    Time frame: Baseline and 3-6 months after treatment

  10. Gestational Age at Delivery

    Gestational age at delivery among live-born infants resulting from embryos included in the study.

    Time frame: At delivery

  11. Change in Antral Follicle Count (AFC)

    Change in antral follicle count from baseline to the follow-up ovarian-reserve assessment.

    Time frame: Baseline and 3-6 months after treatment

  12. Birth Weight

    Birth weight of live-born infants resulting from embryos included in the study.

    Time frame: At birth

  13. Reported Congenital Anomalies

    Number and proportion of live-born infants with one or more congenital anomalies documented at birth.

    Time frame: At birth

08

Study locations

1 site
  • New Hope Fertility Center
    New York, New York 10021, United States
09

References and documents

Publications

  • Gilchrist RB, Ho TM, De Vos M, Sanchez F, Romero S, Ledger WL, Anckaert E, Vuong LN, Smitz J. A fresh start for IVM: capacitating the oocyte for development using pre-IVM. Hum Reprod Update. 2024 Jan 3;30(1):3-25. doi: 10.1093/humupd/dmad023. PubMed 37639630 ↗
  • Vuong LN, Ho VNA, Ho TM, Dang VQ, Phung TH, Giang NH, Le AH, Pham TD, Wang R, Smitz J, Gilchrist RB, Norman RJ, Mol BW. In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Hum Reprod. 2020 Nov 1;35(11):2537-2547. doi: 10.1093/humrep/deaa240. PubMed 32974672 ↗
  • Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4. PubMed 31902102 ↗
  • Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9. PubMed 31399916 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data are not currently planned to be made publicly available. Study results may be published or presented in aggregate form without identifying individual participants.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 5 months is below that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Mar 2027
CompletionEst.
Oct 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07858435
Lead sponsor
New Hope Fertility Center
Collaborators
Embryotools
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Clinical Coordinators
Contact
coordinators@nhfc.com
212-969-7461
John J Zhang, M.D. Ph.D
principal investigator · New Hope Fertility Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion